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Note from the Chief Technical Editor
As Chief Technical Editor, I am delighted and honored to present the
third issue of The University of the Pacific Law Review, Volume 51.
As The University of the Pacific Law Review’s Chief Technical
Editor, my role is to examine the footnotes of each article to ensure
compliance with the Harvard Bluebook and the McGeorge Style Manual.
Each article undergoes multiple rounds of review—first by the staff writers,
then by the primary editors, and finally by the Board of Editors. The
University of the Pacific Law Review strives to output quality, thoughtprovoking articles and the accuracy of footnotes is an important part of this
aim.
Today, the United States is the world’s largest pharmaceutical market.
This issue of Volume 51 explores important legal issues surrounding the
rapidly growing pharmaceutical industry and its regulation. In his article,
Professor Holman voices concerns about the way pharmaceutical companies
use the patent system in the United States and offers suggestions to target the
misuse of patents without impairing the patenting of pharmaceutical
innovations. Professor Rose and Ms. Rice’s article explores the Food and
Drug Administration’s recent Biosimilar Action Plan and analyzes its
effectiveness in balancing innovation and competition in the United States.
The remaining articles in this issue also contain meaningful discussions of the
legal issues surrounding the pharmaceutical industry.
The University of the Pacific Law Review, Volume 51 would not be
possible without the collaboration and efforts of the outstanding Board of
Editors, with whom it has been a true pleasure to work. I owe my sincere
thanks to DJ Mico, my proofreading counterpart, who is tasked with
reviewing the content of each article to eliminate any grammatical or
typographical errors. Also, I would like to specially thank Hayley Graves, our
Editor-in-Chief, for her unmatched dedication to this publication. We
genuinely hope that you enjoy this issue.
Amy Seilliere
Chief Technical Editor
The University of the Pacific Law Review,
Volume 51

